Market Place
Sourcing Support
UK MHRA approves Sentynl ’ Nulibry for injection a first therapy fo MoCD type A
18 Apr 2024 //
PHARMABIZ
Sentynl`s NULIBRY® Authorized For MoCD Type A In UK
16 Apr 2024 //
PR NEWSWIRE
Sentynl Announces Presentation of Study Evaluating the Safety of NULIBRY
07 Sep 2023 //
PR NEWSWIRE
Comharsa`s Nulibry (Fosdenopterin) Receives Approval in Europe
30 Sep 2022 //
EMA
BridgeBio Pharma and Sentynl Receive Marketing Authorization NULIBRY®
20 Sep 2022 //
GLOBENEWSWIRE
BridgeBio, Sentynl and Medison Pharma Announce Approval in Israel for NULIBRY
10 Aug 2022 //
GLOBENEWSWIRE
BridgeBio and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY
25 Jul 2022 //
PRNEWSWIRE
Zydus’ subsidiary Sentynl inks asset purchase agreement of BridgeBio’s Nulibry
09 Mar 2022 //
PHARMABIZ
BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval
01 Mar 2021 //
ENDPTS
FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A
01 Mar 2021 //
PHARMATIMES
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A
28 Feb 2021 //
FDA
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A
26 Feb 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.